Latest ACE inhibitor Stories
DENVER, Nov. 22, 2010 /PRNewswire/ -- On November 20 at the American Society of Nephrology (ASN) 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A.
A trio of studies published in the American Journal of Hypertension offers new insight into the field of personalized medicine, challenging conventional approaches to treating the hypertension suffered by one-in-three US adults.
PARSIPPANY, N.J., July 26 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that the U.S.
Factors of hormone metabolism that may make African-Americans more susceptible.
With a concern that the automatic reporting of estimated glomerular filtration rate (GFR; the flow rate of filtered fluid through the kidney, which is used to define the stage and severity of chronic kidney disease) may result in unnecessary referrals by physicians, new research indicates that automated laboratory reporting was associated with a significant increase in first-time visits to a kidney specialist, particularly among those at increased risk of late detection of kidney disease...
PARSIPPANY, N.J., Feb. 11 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that the U.S.
Researchers from Boston University School of Medicine (BUSM) have found that angiotensin receptor blockers (ARBs)â€”a particular class of anti-hypertensive medicinesâ€”are associated with a striking decrease in the occurrence and progression of dementia.
New research from the Northwestern University Feinberg School of Medicine has found that an alternative therapy may be possible for treating some types of hypertension using an enzyme called ACE2.
Study highlights: -- A study of nearly 4,000 heart failure patients finds that a larger dose of angiotensin receptor blockers (ARBs) works better than a smaller dose. -- The higher dose was associated with a 10.1 percent relative risk reduction (in the combined primary end-point of all-cause mortality and hospitalization for heart failure) versus the lower dose, mostly due to a reduction in the risk of heart failure hospitalizations.
LEIDEN, The Netherlands, November 17 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
- The parings of haberdine; also, any kind of fragments.